Transforming cancer treatment and advancing new therapies through empowered science

Webcast ImageWebcast
First Quarter 2015 Financial Results Conference Call (Live)
04/30/15 at 4:30 p.m. ET
First Quarter 2015 Financial Results Conference Call
Thursday, April 30, 2015 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited is commercially available for two indications in more than 50 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs designed to address the unmet medical needs of people with cancer, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics’ ADC technology is employed by a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our proprietary approach to empowering antibodies.

Download Documentation  Corporate Fact Sheet
Download Documentation  2014 Annual Report
Download Documentation  2015 Proxy Statement
Investor Contact
Peggy Pinkston
Executive Director, Corporate Communications
PHONE: (425) 527-4160
FAX: (425) 527-4001
EMAIL: ppinkston@seagen.com

Media Contact
Tricia Larson
Director, Public Relations
PHONE: 425-527-4180
EMAIL: tlarson@seagen.com
Stock Quote
SGEN (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$37.14
Change (%) Stock is Down 0.36 (0.96%)
Volume794,243
Data as of 04/24/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >
DateTitle 
04/20/15FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the AETHERA Setting for the Post-Transplant Consolidation Treatment of Hodgkin Lymphoma Patients at High Risk of Relapse
-PDUFA Action Date August 18, 2015- -Submission of Supplemental BLA Based on Positive Phase 3 AETHERA Clinical Trial Results Recently Published in The Lancet- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 20, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for ADCETRIS (brentuximab vedotin) in the AETH... 
Printer Friendly Version
04/16/15Seattle Genetics Highlights Broad Presence at the American Association for Cancer Research (AACR) Annual Meeting
-Multiple Data Presentations Support Antibody-Drug Conjugate (ADC) Program Development Plans and Highlight Technology Advances- -SEA-CD40 Immuno-Oncology Preclinical Data Show Potent Activation of Antigen Presenting Cells- -ADCETRIS® (Brentuximab Vedotin) Shown to Induce Immunogenic Cell Death in Preclinical Studies; Combination Clinical Trials Planned with Nivolumab- -Senior Management to Present in Multiple Sessions on Ce... 
Printer Friendly Version
04/13/15Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2015 Financial Results on April 30, 2015
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 13, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2015 financial results on Thursday, April 30 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thu... 
Printer Friendly Version
02/25/15Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 25, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Cowen and Company 35th Annual Health Care Conference Tuesday, March 3, 8:40 a.m. Eastern Tim... 
Printer Friendly Version
02/18/15Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 18, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 AETHERA trial of ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at high risk of relapse. A... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.